The Ki-67 labeling index has been reported to discriminate luminal A (LA)-like and luminal B-like subtypes in patients with hormone-receptor positive, HER2-negative breast cancer. We analyzed prognostic factors including progesterone receptor (PR) expression. PR expression and tumor size were independent prognostic factors in the LA-like subtype, and the LA/PR-negative subtype had the higher risk of recurrence, especially late recurrence. , and LB-like subtypes, the 12-year disease-free survival (DFS) rates were 94.8%, 81.6%, and 79.7% (P ¼ .03), and breast cancer-specific survival (BCSS) rates were 98.4%, 97.4%, and 92.0%, respectively (P ¼ .05). Late recurrence occurred in LA/PR À subtype, and differences in prognosis between LA/PR þ and LA/PR À subtypes emerged >5 years after surgery. Twelve-year DFS rates of the LA/PR À subtype were almost equal to those of the LB-like subtype, whereas 12-year BCSS of the LA/PR À subtype was superior to that of the LB-like subtype. In multivariate analysis, PR expression and tumor size were significant or nearly significant prognostic factors. Conclusion: PR expression and tumor size were independent prognostic factors in the LA-like subtype, and the LA/PR À subtype had the higher risk of recurrence, especially late recurrence, than the LA/PR þ subtype. In LA-like breast cancers, stratification of prognosis according to PR expression and tumor size is important.
Introduction
Breast cancer is the most common cancer in women. The mortality in Western countries is decreasing because of early detection and effective systemic adjuvant therapy. In Japan, however, the incidence is still increasing, and more than 70,000 cases were newly diagnosed in 2010, with more than 12,000 deaths in 2012. 1 More than half of newly diagnosed Japanese breast cancer patients are estimated to have node-negative, invasive disease, resulting in local 1 or distant recurrence within 10 years of the diagnosis in 10% to 15% of these patients. 2, 3 Therefore, it has been important to establish criteria for identifying the high-risk patient groups for whom adjuvant chemotherapy might be beneficial. Breast cancer has been reported to be a heterogeneous disease in previous studies in which a molecular subtype classification of invasive breast cancers using gene expression analysis was correlated with chemotherapeutic response and clinical outcome. 4 In clinical practice, simplified intrinsic subtype classification using immunohistochemistry (IHC) is widely used for treatment choice in the neoadjuvant or adjuvant settings. [5] [6] [7] Hormone receptor (HR)-positive breast cancers are in practice classified into luminal A (LA)-like subtype and luminal B (LB)-like subtype with or without HER2 overexpression. The LA-like subtype is shown to express high levels of HR and a favorable prognosis. In contrast, the LB-like subtype presents with a worse prognosis compared with the LA-like subtype. 8 In discriminating between LA-like and LB-like subtypes without HER2 overexpression, Ki-67 labeling index (LI) has been shown to be useful. 7 We previously reported that Ki-67 LI was useful as a prognosticator to identify high-risk node-negative luminal/HER2-negative (HER2 À ) tumors in Japanese patients regardless of 3 different cutoff values. 9 In these cases, it was shown that any of the Ki-67 LI cutoff values (10%, 14%, and 20%), could be applicable in making determinations between high-risk and lowrisk luminal/HER2 À node-negative invasive breast cancers.
A recent study showed that progesterone receptor (PR) expression as well as Ki-67 LI using IHC were important prognostic factors in luminal/HER2
À breast cancer, which suggests the utility of PR as a marker for differentiation between LA-like and LB-like subtypes. 6 Actually, previous reports revealed that PR expression was a prognostic factor in HR þ breast cancer. 10 In this study, we evaluated the prognostic significance of PR expression using the cohort in whom Ki-67 LI was previously examined 9 and investigated optimal cutoff levels of Ki-67 LI and PR expression.
Patients and Methods

Patient Selection and Data Collection
Details of patient selection were shown in our previous study. 9 Briefly, of 530 consecutive patients with pathologically nodenegative invasive primary breast cancer, 369 (70%) with HRpositive and HER2 À (luminal/HER2 À ) tumors were identified.
We reviewed the medical charts and extracted patient data including age, regimens of adjuvant chemotherapy and endocrine therapies, and dates of recurrence, death, or the last follow-up examination. Methods for formalin-fixed paraffin blocks, routine pathological evaluation, IHC for estrogen receptor (ER), PR, HER2, and Ki-67, fluorescence in situ hybridization (FISH) for HER2, and tissue microarray construction were described in our previous report. 9 The present study was approved by the institutional review board of the National Cancer Center, Tokyo, Japan.
Evaluation of IHC
The methods for evaluation of IHC have been shown in our previous report. 9 Briefly, ER was judged as positive when the Allred score was !3 and as negative when the score was 2 11 and PR was evaluated with 3 cutoff levels of 10%, 20%, and 30%. HER2 was judged as positive when the IHC score was 3þ or when it was 2þ 
Statistical Analyses
Statistical analyses were performed using IBM SPSS (SPSS Inc, Chicago, IL). Correlation analyses were performed using the c 2 test
for categorical variables. The interval from the date of initial surgery to disease recurrence was defined as disease-free survival (DFS), and the interval from the date of surgery to death from breast cancer or the last follow-up examination was defined as breast cancer-specific survival (BCSS). Death from another disease was regarded as censored. DFS and BCSS curves were drawn using the KaplaneMeier method and compared using the log rank test. Cox univariate and multivariate regression analyses were performed to evaluate prognostic significance of each parameter in patients with luminal-subtype breast cancers. In all analyses, differences were considered significant at P < .05.
Results
Correlation Between Ki-67 LI and PR Expression
Of 369 tumors, we excluded 1 case because of insufficient material for evaluation of PR expression. The details of the 368 luminal/HER2 À breast cancer cases are shown in Table 1 . There were 187 patients (51%) who had received adjuvant hormonal therapy with tamoxifen and 153 (41%) who had received adjuvant chemotherapy. The median duration of follow-up for all 368 patients was 118 (range, 0.6-160) months. Overall, 38 recurrences and 14 deaths from breast cancer occurred.
The correlation between the Ki-67 LI and PR expression is shown in Table 2 . Although the Ki-67 LI was !10% in 221 (60%), !14% in 163 (44%), and !20% in 87 (24%) of the tumors, PR expression was <10% in 66 (18%), <20% in 115 (31%), and <30% in 138 (37% breast cancers increased as the cutoff level for PR expression went higher. Simultaneously, the higher the cutoff level of Ki-67 LI, the more low Ki-67 LI breast cancers were negative for PR. Accordingly, in case of the 20% Ki-67 LI cutoff level, PR expression with any cutoff level and Ki-67 LI were inversely associated (PR 10%, P < .001; PR 20%, P < .001; PR 30%, P ¼ .003), indicating that 14% to 34% of low Ki-67 LI breast cancers were negative for PR. When Ki-67 LI was divided into 6 groups with <5, 5 to 10, 10 to 14, 14 to 20, 20 to 30, and >30%, as shown in Figure 1 , in breast cancers with high Ki-67 LI the percentage of PR-negative breast cancers increased, showing that Ki-67 LI and PR expression had a significant inverse correlation. Interestingly, when Ki-67 LI was !20%, the number of PR À breast cancers greatly increased. The percentages of PR À breast cancers with <20%
Ki-67 LI and !20% Ki-67 LI were 26% and 49%, respectively (P < .001).
Ki-67 LI and PR Expression as a Prognostic Marker for Luminal-Like Subtypes
To investigate the prognostic significance of PR expression, we examined the survival analyses for patients stratified according to 3 subtypes (ie, LA-like
, and LB-like subtypes). When the cutoff value of PR expression was set at 10% or 30%, there was no significant difference in DFS between LA/PR þ and LA/PR À breast cancers. However, as shown in Figure 2A , with a PR expression cutoff level of 20%, DFS was , and LB-like subtypes, and the 12-year BCSS rates were 98.4%, 97.5%, and 91.9% in these 3 groups, respectively (P ¼ .04). Unlike DFS, the BCSS for patients with the LA/PR À subtype was better than that for the LB-like subtype and close to that for the LA/PR þ subtype.
Cox Univariate and Multivariate Analyses of DFS
In Cox univariate analysis of DFS for patients with the LA-like subtype, it was shown that large tumor size was a significant indicator of worse clinical outcome (hazard ratio, 3.36; 95% confidence interval [CI], 1.18-9.58; P ¼ .02). Although the significance was marginal, negative PR expression with a cutoff level of 20% also tended to be correlated with worse clinical outcomes (hazard ratio, 2.81; 95% CI, 0.98-8.00; P ¼ .05; Table 3 ). Likewise, a multivariate analysis including pT factor and PR showed that both of these factors remained significant or marginally significant prognostic factors (tumor size, hazard ratio, 3.36, 95% CI, 1.18-9.59, P ¼ .02; PR, hazard ratio, 2.83, 95% CI, 0.99-8.07, P ¼ .05; Table 4 ).
In univariate analysis of BCSS for patients with the LA-like subtype, no factor had any prognostic significance (Table 5 ). This might be because a few number of events occurred in BCSS. However, in univariate analysis of DFS for patients with the LB-like subtype, unlike the LA-like subtype, there was no significant prognostic factor (data not shown), indicating that clinical outcome in patients with LB-like subtype is influenced by Ki-67 LI but not PR expression.
Discussion
For decades, the predictive and prognostic significance of PR expression in breast cancer have been debated, and so far there have been equivocal data about the role of PR expression in HR þ breast cancer. 10, 14 In the present study we showed that PR expression was a marginally significant independent prognostic factor in the LA-like subtype and that differences in prognosis between LA/PR þ and LA/PR À became evident !5 years after surgery.
A recent meta-analysis has shown a similar reduction in the risk of recurrence in ER þ /PR þ and ER þ /PR À early breast cancers treated with adjuvant tamoxifen. 10 Simultaneously, PR expression had no influence on the efficacy of an aromatase inhibitor over tamoxifen in ER þ early breast cancer patients, 15, 16 whereas baseline risk of recurrence is higher in the PR À subgroup than the PR þ subgroup in ER þ breast cancer patients. 10 These findings revealed that PR expression is a prognostic but not a predictive factor. There have been several molecular mechanisms with the loss of PR expression in breast cancer reported so far, in which PR is found to be the end product of estrogen action, and the absence of PR expression means nonfunctional ER. 17 In addition, recent reports have shown that aberrant growth factor signaling resulted in reduction of PR expression. 18 Indeed, in our cohort including luminal/HER2 þ subtype, luminal/HER2 þ breast cancers are more likely to be negative for PR expression compared with luminal/ HER2 À breast cancers (data not shown). All these suggested mechanisms of the loss of PR expression could be associated with highly malignant characteristics leading to poor clinical outcomes. Interestingly, the present study has shown that PR expression affects late recurrence in the LA-like subtype. Therefore, BCSS for LA/PR À was as good as that for the LA/PR þ subtype over 10 years after surgery. It is assumed that differences in BCSS between LA/ PR þ and LA/PR À would emerge later, even 20 years after surgery.
Because the extended use of hormonal therapy beyond 5 years could prevent late recurrences, 19, 20 it is important to clarify the risk factors of late recurrence in patient selection for its extended use. Previous studies have reported that proliferation markers and Grade were important prognostic factors for early recurrence within 5 years after diagnosis in HR þ breast cancer, but these studies failed to predict later recurrences. 21 Simultaneously, several molecular tests that give weight to proliferation and cell cycle progression such as Oncotype DX (Genomic Health, Redwood City, CA) and Mammaprint (Agendia, Amsterdam) could not significantly predict late recurrences. 22, 23 These findings suggest that the molecular mechanism might be different between early and late recurrence. Indeed, gene signatures related to recurrence risk have been shown to differ between early and late recurrence. 24, 25 To date, there have been no reports showing PR expression as a prognostic marker for late recurrence. However, in a gene expression analysis, HR signaling was shown to be a risk factor of late recurrence. The EndoPredict, a gene signature that combines proliferation-related genes and ER signaling genes, has been reported to predict early and late recurrences. 24 Interestingly, the risk of late recurrences was significantly higher in breast cancers with the higher risk score estimated from expression of 5 ER signaling genes, RBBP8 (retinoblastoma-binding protein 8), IL6ST (interleukin 6 signal transducer), AZGP1 (alpha-2-glycoprotein 1, zinc-binding), MGP (matrix Gla protein), and STC2 (stanniocalcin 2), than in those with the lower risk score. 24 Some of these 5 genes are shown to be regulated by progesterone. Therefore, a low expression level of PR is implied to be associated with risk of late recurrence. 26, 27 Similarly with EndoPredict, Breast Cancer Index (BCI) and PAM50 are able to predict late recurrences as well as early recurrences in HR þ breast cancer. 22, 25, [28] [29] [30] BCI consists of the Molecular Grade Index (MGI), which depends on proliferationrelated genes, and HOXB13 (homeobox B13):IL17BR (interleukin 17 receptor B) ratio (H/I). MGI is associated with early but not late recurrence, whereas H/I has a greater prognostic power in late recurrences than in early recurrences. 25 In a study that showed the prognostic significance of H/I, PR expression was not associated with late recurrence risk. 31 However, in that study, the cutoff level of PR expression was much lower than 20%. In the present study, a PR cutoff level of 10% did not show a significant difference in prognosis in LA-like breast cancers. In these points, the results of the present study are consistent with those of previous studies that showed the importance of a 20% cutoff level for PR in IHC according to the data of PAM50. 6, 28, 29 We also showed tumor size as an important prognostic factor. Although nowadays we give weight to breast cancer biology with subtypes in risk estimation, tumor burden such as tumor size and nodal status remain important prognostic factors. 32 It has been reported that tumor size and nodal status were independent prognostic factors for late recurrence in patients with ER þ breast cancer 
Conclusion
We showed that PR expression and tumor size were significant or marginally significant independent prognostic factors in the LA-like subtype and that differences in prognosis between LA/PR þ and LA/PR À became evident !5 years after surgery, resulting in better prognosis in LA/PR À than in the LB-like subtype. In LA-like breast cancer, stratification of prognosis according to PR expression and tumor size is important.
Clinical Practice Points
The node-negative invasive breast cancer of the LA-like subtype is defined as HR-positive, HER2-negative, and Ki-67-low subgroup and is correlated with good prognosis. Nonetheless, a minority of patients with these characteristics suffer from relapse of and death from LA-like breast cancer.
In the present study, we examined 205 consecutive patients who received surgical therapy to node-negative LA-like primary invasive breast cancer, and 149 (73%) and 56 cases (27%) of these 205 were PR þ (20% or more cells) and PR À (< 20% of cells), respectively. In this LA-like group, in addition to pathological tumor size, PR negativity was a significant indicator of a lower DFS rate: 12-year DFS rates were 94.8% in the LA-like group with positive PR and 81.6% in the LA-like group with negative PR status. Therefore, the status of PR in node-negative LA-like invasive carcinoma could be useful in the consideration of adjuvant therapy.
